Merck & Company, Inc. vs NovoCure Limited — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
NVCR
NovoCure Limited
$16.62
▲ 9.27%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.4/10

Q·Score Breakdown

6.7
Neutral
Overall
5.4
Bearish
6.2
Quality
1
7
Health
7.4
6.2
Growth
6.7
7.2
Valuation
6.5
7.1
Sentiment
6.8
MRK

Forward P/E of 11.5× is low relative to sector peers.

NVCR

Healthy balance sheet and financial position.

currently unprofitable (-26% margin).

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $25.21 (+51.7%)
7 analysts

Fundamentals

MRK
NVCR
31.5×
Trailing P/E
11.5×
Forward P/E
-14.3×
13.6%
Profit Margin
-25.7%
76.6%
Gross Margin
75.4%
ROE
-50.0%
4.9%
Revenue Growth
12.3%
Earnings Growth
0.28
Beta
0.82
Price / Book
$277.0B
Market Cap
$1.9B
$73 – $125
52-Week Range
$10 – $20

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →